Lipid Nanoparticles Immunogenicity & Toxicity | December 6-8, 2022
pharmaphorum
AUGUST 16, 2022
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. .
52 
Let's personalize your content